Moderna Inc. (MRNA) announced that the U.S. Food and Drug Administration has approved its respiratory syncytial virus (RSV) vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease (LRTD) caused by RSV in adults aged 18-59 who are at increased risk.
The approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older.
The company intends to have mRESVIA available for both younger adults at increased risk (ages 18-59) and older adults (ages 60+) in the U.S. for the 2025-2026 respiratory virus season.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.